nodes	percent_of_prediction	percent_of_DWPC	metapath
Ximelagatran—F2—forelimb—Parkinson's disease	0.0461	0.532	CbGeAlD
Ximelagatran—F2—PAR1-mediated thrombin signaling events—ADRBK2—Parkinson's disease	0.0432	0.0473	CbGpPWpGaD
Ximelagatran—F2—Common Pathway—FGB—Parkinson's disease	0.0314	0.0344	CbGpPWpGaD
Ximelagatran—F2—Blood Clotting Cascade—FGB—Parkinson's disease	0.0267	0.0293	CbGpPWpGaD
Ximelagatran—F2—Cell surface interactions at the vascular wall—MERTK—Parkinson's disease	0.0222	0.0243	CbGpPWpGaD
Ximelagatran—F2—Regulation of IGF Activity by IGFBP—IGF2—Parkinson's disease	0.0196	0.0214	CbGpPWpGaD
Ximelagatran—F2—Formation of Fibrin Clot (Clotting Cascade)—FGB—Parkinson's disease	0.018	0.0197	CbGpPWpGaD
Ximelagatran—F2—Platelet Aggregation (Plug Formation)—FGB—Parkinson's disease	0.0176	0.0193	CbGpPWpGaD
Ximelagatran—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—Parkinson's disease	0.0157	0.0172	CbGpPWpGaD
Ximelagatran—CYP2C9—CYP2E1 reactions—CYP2D6—Parkinson's disease	0.0145	0.0159	CbGpPWpGaD
Ximelagatran—F2—Vitamin B12 Metabolism—INSR—Parkinson's disease	0.0144	0.0158	CbGpPWpGaD
Ximelagatran—CYP2C9—CYP2E1 reactions—CYP2E1—Parkinson's disease	0.0133	0.0145	CbGpPWpGaD
Ximelagatran—F2—Cell surface interactions at the vascular wall—MAG—Parkinson's disease	0.0127	0.0139	CbGpPWpGaD
Ximelagatran—F2—Complement and Coagulation Cascades—FGB—Parkinson's disease	0.0121	0.0133	CbGpPWpGaD
Ximelagatran—F2—G alpha (q) signalling events—DGKQ—Parkinson's disease	0.0119	0.013	CbGpPWpGaD
Ximelagatran—F2—Folate Metabolism—INSR—Parkinson's disease	0.0117	0.0129	CbGpPWpGaD
Ximelagatran—F2—Peptide ligand-binding receptors—GPR37—Parkinson's disease	0.0117	0.0128	CbGpPWpGaD
Ximelagatran—F2—Gastrin-CREB signalling pathway via PKC and MAPK—DGKQ—Parkinson's disease	0.0106	0.0116	CbGpPWpGaD
Ximelagatran—F2—Platelet activation, signaling and aggregation—DGKQ—Parkinson's disease	0.0104	0.0114	CbGpPWpGaD
Ximelagatran—F2—Vitamin B12 Metabolism—SOD1—Parkinson's disease	0.0101	0.0111	CbGpPWpGaD
Ximelagatran—F2—Selenium Micronutrient Network—INSR—Parkinson's disease	0.00933	0.0102	CbGpPWpGaD
Ximelagatran—F2—Vitamin B12 Metabolism—SOD2—Parkinson's disease	0.00912	0.00999	CbGpPWpGaD
Ximelagatran—CYP2C9—Xenobiotics—CYP2D6—Parkinson's disease	0.009	0.00986	CbGpPWpGaD
Ximelagatran—F2—G alpha (q) signalling events—GRK5—Parkinson's disease	0.009	0.00985	CbGpPWpGaD
Ximelagatran—F2—cardiovascular system—Parkinson's disease	0.00884	0.102	CbGeAlD
Ximelagatran—F2—IL1 and megakaryotyces in obesity—IL1B—Parkinson's disease	0.00871	0.00954	CbGpPWpGaD
Ximelagatran—CYP2C9—Tamoxifen metabolism—CYP2D6—Parkinson's disease	0.00866	0.00948	CbGpPWpGaD
Ximelagatran—F2—Folate Metabolism—SOD1—Parkinson's disease	0.00824	0.00902	CbGpPWpGaD
Ximelagatran—CYP2C9—Xenobiotics—CYP2E1—Parkinson's disease	0.00823	0.00901	CbGpPWpGaD
Ximelagatran—F2—Gastrin-CREB signalling pathway via PKC and MAPK—GRK5—Parkinson's disease	0.00805	0.00881	CbGpPWpGaD
Ximelagatran—F2—Vitamin B12 Metabolism—MTHFR—Parkinson's disease	0.00803	0.00879	CbGpPWpGaD
Ximelagatran—CYP2C9—Tamoxifen metabolism—CYP2E1—Parkinson's disease	0.00792	0.00867	CbGpPWpGaD
Ximelagatran—F2—Class A/1 (Rhodopsin-like receptors)—GPR37—Parkinson's disease	0.00786	0.00861	CbGpPWpGaD
Ximelagatran—F2—Peptide ligand-binding receptors—PENK—Parkinson's disease	0.00755	0.00827	CbGpPWpGaD
Ximelagatran—F2—Vitamin B12 Metabolism—APOE—Parkinson's disease	0.00748	0.00818	CbGpPWpGaD
Ximelagatran—F2—Folate Metabolism—SOD2—Parkinson's disease	0.00742	0.00812	CbGpPWpGaD
Ximelagatran—F2—FOXA2 and FOXA3 transcription factor networks—INS—Parkinson's disease	0.00719	0.00787	CbGpPWpGaD
Ximelagatran—F2—Folate Metabolism—GPX1—Parkinson's disease	0.00708	0.00775	CbGpPWpGaD
Ximelagatran—F2—Peptide ligand-binding receptors—PDYN—Parkinson's disease	0.00691	0.00756	CbGpPWpGaD
Ximelagatran—F2—Regulation of Actin Cytoskeleton—FGF20—Parkinson's disease	0.00684	0.00749	CbGpPWpGaD
Ximelagatran—F2—spinal cord—Parkinson's disease	0.00673	0.0777	CbGeAlD
Ximelagatran—F2—Selenium Micronutrient Network—SOD1—Parkinson's disease	0.00655	0.00717	CbGpPWpGaD
Ximelagatran—F2—Folate Metabolism—MTHFR—Parkinson's disease	0.00653	0.00715	CbGpPWpGaD
Ximelagatran—F2—G alpha (q) signalling events—GRM5—Parkinson's disease	0.00651	0.00712	CbGpPWpGaD
Ximelagatran—F2—Vitamin B12 Metabolism—INS—Parkinson's disease	0.00639	0.00699	CbGpPWpGaD
Ximelagatran—F2—Hemostasis—DOCK3—Parkinson's disease	0.00601	0.00658	CbGpPWpGaD
Ximelagatran—F2—Hemostasis—MERTK—Parkinson's disease	0.00601	0.00658	CbGpPWpGaD
Ximelagatran—F2—GPCR ligand binding—GPR37—Parkinson's disease	0.00599	0.00656	CbGpPWpGaD
Ximelagatran—F2—head—Parkinson's disease	0.00598	0.0691	CbGeAlD
Ximelagatran—F2—Selenium Micronutrient Network—SOD2—Parkinson's disease	0.00589	0.00645	CbGpPWpGaD
Ximelagatran—F2—Gastrin-CREB signalling pathway via PKC and MAPK—GRM5—Parkinson's disease	0.00582	0.00637	CbGpPWpGaD
Ximelagatran—F2—nervous system—Parkinson's disease	0.00567	0.0655	CbGeAlD
Ximelagatran—F2—Selenium Micronutrient Network—GPX1—Parkinson's disease	0.00562	0.00616	CbGpPWpGaD
Ximelagatran—F2—central nervous system—Parkinson's disease	0.00546	0.063	CbGeAlD
Ximelagatran—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—Parkinson's disease	0.00539	0.0059	CbGpPWpGaD
Ximelagatran—F2—Hemostasis—DGKQ—Parkinson's disease	0.00535	0.00586	CbGpPWpGaD
Ximelagatran—F2—Folate Metabolism—INS—Parkinson's disease	0.0052	0.00569	CbGpPWpGaD
Ximelagatran—F2—Selenium Micronutrient Network—MTHFR—Parkinson's disease	0.00519	0.00568	CbGpPWpGaD
Ximelagatran—F2—Class A/1 (Rhodopsin-like receptors)—PENK—Parkinson's disease	0.00507	0.00555	CbGpPWpGaD
Ximelagatran—F2—Vitamin B12 Metabolism—IL1B—Parkinson's disease	0.00477	0.00522	CbGpPWpGaD
Ximelagatran—F2—G alpha (q) signalling events—TAC1—Parkinson's disease	0.00473	0.00518	CbGpPWpGaD
Ximelagatran—F2—Peptide ligand-binding receptors—TAC1—Parkinson's disease	0.00467	0.00511	CbGpPWpGaD
Ximelagatran—F2—Class A/1 (Rhodopsin-like receptors)—PDYN—Parkinson's disease	0.00463	0.00507	CbGpPWpGaD
Ximelagatran—F2—Angiopoietin receptor Tie2-mediated signaling—MAPK8—Parkinson's disease	0.00444	0.00486	CbGpPWpGaD
Ximelagatran—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—Parkinson's disease	0.00441	0.00483	CbGpPWpGaD
Ximelagatran—F2—brain—Parkinson's disease	0.00434	0.05	CbGeAlD
Ximelagatran—F2—Gastrin-CREB signalling pathway via PKC and MAPK—TAC1—Parkinson's disease	0.00423	0.00463	CbGpPWpGaD
Ximelagatran—F2—Platelet activation, signaling and aggregation—FGB—Parkinson's disease	0.00422	0.00462	CbGpPWpGaD
Ximelagatran—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—Parkinson's disease	0.0042	0.0046	CbGpPWpGaD
Ximelagatran—F2—G alpha (q) signalling events—ADRBK1—Parkinson's disease	0.00419	0.00459	CbGpPWpGaD
Ximelagatran—F2—Selenium Micronutrient Network—INS—Parkinson's disease	0.00413	0.00452	CbGpPWpGaD
Ximelagatran—CYP2C9—Phase 1 - Functionalization of compounds—MAOB—Parkinson's disease	0.00408	0.00446	CbGpPWpGaD
Ximelagatran—F2—GPCR ligand binding—GRM4—Parkinson's disease	0.00407	0.00446	CbGpPWpGaD
Ximelagatran—F2—Metabolism of proteins—HSPA9—Parkinson's disease	0.00402	0.0044	CbGpPWpGaD
Ximelagatran—F2—Folate Metabolism—IL1B—Parkinson's disease	0.00388	0.00424	CbGpPWpGaD
Ximelagatran—F2—GPCR ligand binding—PENK—Parkinson's disease	0.00386	0.00422	CbGpPWpGaD
Ximelagatran—F2—Gastrin-CREB signalling pathway via PKC and MAPK—ADRBK1—Parkinson's disease	0.00375	0.00411	CbGpPWpGaD
Ximelagatran—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2D6—Parkinson's disease	0.00374	0.00409	CbGpPWpGaD
Ximelagatran—CYP2C9—Oxidation by Cytochrome P450—CYP2D6—Parkinson's disease	0.00369	0.00404	CbGpPWpGaD
Ximelagatran—F2—Class A/1 (Rhodopsin-like receptors)—ADORA2A—Parkinson's disease	0.00366	0.00401	CbGpPWpGaD
Ximelagatran—F2—GPCR ligand binding—PDYN—Parkinson's disease	0.00353	0.00386	CbGpPWpGaD
Ximelagatran—CYP2C9—cardiovascular system—Parkinson's disease	0.00352	0.0406	CbGeAlD
Ximelagatran—F2—Angiopoietin receptor Tie2-mediated signaling—TNF—Parkinson's disease	0.00351	0.00385	CbGpPWpGaD
Ximelagatran—F2—Vitamin B12 Metabolism—TNF—Parkinson's disease	0.00346	0.00379	CbGpPWpGaD
Ximelagatran—F2—Hemostasis—MAG—Parkinson's disease	0.00345	0.00378	CbGpPWpGaD
Ximelagatran—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2E1—Parkinson's disease	0.00342	0.00374	CbGpPWpGaD
Ximelagatran—F2—GPCR downstream signaling—DGKQ—Parkinson's disease	0.00338	0.0037	CbGpPWpGaD
Ximelagatran—CYP2C9—Oxidation by Cytochrome P450—CYP2E1—Parkinson's disease	0.00337	0.00369	CbGpPWpGaD
Ximelagatran—F2—GPCR ligand binding—GRM5—Parkinson's disease	0.00328	0.00359	CbGpPWpGaD
Ximelagatran—F2—G alpha (q) signalling events—EDN1—Parkinson's disease	0.00325	0.00356	CbGpPWpGaD
Ximelagatran—F2—Peptide ligand-binding receptors—EDN1—Parkinson's disease	0.00321	0.00351	CbGpPWpGaD
Ximelagatran—F2—Class A/1 (Rhodopsin-like receptors)—HTR1A—Parkinson's disease	0.00318	0.00348	CbGpPWpGaD
Ximelagatran—F2—Platelet activation, signaling and aggregation—SOD1—Parkinson's disease	0.00313	0.00343	CbGpPWpGaD
Ximelagatran—F2—Class A/1 (Rhodopsin-like receptors)—TAC1—Parkinson's disease	0.00313	0.00343	CbGpPWpGaD
Ximelagatran—F2—Selenium Micronutrient Network—IL1B—Parkinson's disease	0.00308	0.00337	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—DGKQ—Parkinson's disease	0.00307	0.00336	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—GPR37—Parkinson's disease	0.00307	0.00336	CbGpPWpGaD
Ximelagatran—F2—Class A/1 (Rhodopsin-like receptors)—DRD1—Parkinson's disease	0.00307	0.00336	CbGpPWpGaD
Ximelagatran—CYP2C9—Phase 1 - Functionalization of compounds—CYP2D6—Parkinson's disease	0.00303	0.00332	CbGpPWpGaD
Ximelagatran—F2—Platelet activation, signaling and aggregation—IGF2—Parkinson's disease	0.00298	0.00326	CbGpPWpGaD
Ximelagatran—F2—Class A/1 (Rhodopsin-like receptors)—DRD3—Parkinson's disease	0.00297	0.00326	CbGpPWpGaD
Ximelagatran—F2—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—Parkinson's disease	0.00291	0.00318	CbGpPWpGaD
Ximelagatran—CYP2C9—Arachidonic acid metabolism—GPX1—Parkinson's disease	0.00287	0.00314	CbGpPWpGaD
Ximelagatran—F2—Metabolism of proteins—RPL6—Parkinson's disease	0.00286	0.00313	CbGpPWpGaD
Ximelagatran—F2—G alpha (q) signalling events—HTR2A—Parkinson's disease	0.00284	0.00311	CbGpPWpGaD
Ximelagatran—F2—Folate Metabolism—TNF—Parkinson's disease	0.00281	0.00308	CbGpPWpGaD
Ximelagatran—F2—Platelet activation, signaling and aggregation—HGF—Parkinson's disease	0.00281	0.00308	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—PPP1R1B—Parkinson's disease	0.00281	0.00308	CbGpPWpGaD
Ximelagatran—F2—Vitamin B12 Metabolism—IL6—Parkinson's disease	0.00279	0.00306	CbGpPWpGaD
Ximelagatran—F2—GPCR ligand binding—ADORA2A—Parkinson's disease	0.00279	0.00305	CbGpPWpGaD
Ximelagatran—CYP2C9—Phase 1 - Functionalization of compounds—CYP2E1—Parkinson's disease	0.00277	0.00303	CbGpPWpGaD
Ximelagatran—F2—Metabolism of proteins—ATP6AP2—Parkinson's disease	0.00271	0.00297	CbGpPWpGaD
Ximelagatran—F2—Class A/1 (Rhodopsin-like receptors)—DRD2—Parkinson's disease	0.00269	0.00294	CbGpPWpGaD
Ximelagatran—F2—Class A/1 (Rhodopsin-like receptors)—HTR7—Parkinson's disease	0.00269	0.00294	CbGpPWpGaD
Ximelagatran—F2—GPCR downstream signaling—GRK5—Parkinson's disease	0.00256	0.00281	CbGpPWpGaD
Ximelagatran—F2—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Parkinson's disease	0.00254	0.00278	CbGpPWpGaD
Ximelagatran—F2—Metabolism of proteins—DCTN1—Parkinson's disease	0.00248	0.00272	CbGpPWpGaD
Ximelagatran—CYP2C9—Biological oxidations—GSTA4—Parkinson's disease	0.00243	0.00266	CbGpPWpGaD
Ximelagatran—F2—GPCR ligand binding—HTR1A—Parkinson's disease	0.00242	0.00265	CbGpPWpGaD
Ximelagatran—CYP2C9—Metapathway biotransformation—GSTA4—Parkinson's disease	0.0024	0.00262	CbGpPWpGaD
Ximelagatran—F2—GPCR ligand binding—TAC1—Parkinson's disease	0.00238	0.00261	CbGpPWpGaD
Ximelagatran—F2—GPCR ligand binding—DRD1—Parkinson's disease	0.00234	0.00256	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—GRK5—Parkinson's disease	0.00233	0.00255	CbGpPWpGaD
Ximelagatran—F2—GPCR downstream signaling—GRM4—Parkinson's disease	0.0023	0.00252	CbGpPWpGaD
Ximelagatran—CYP2C9—Phase 1 - Functionalization of compounds—MAOA—Parkinson's disease	0.00228	0.0025	CbGpPWpGaD
Ximelagatran—F2—Folate Metabolism—IL6—Parkinson's disease	0.00227	0.00249	CbGpPWpGaD
Ximelagatran—F2—GPCR ligand binding—DRD3—Parkinson's disease	0.00226	0.00248	CbGpPWpGaD
Ximelagatran—F2—Selenium Micronutrient Network—TNF—Parkinson's disease	0.00223	0.00245	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—VPS35—Parkinson's disease	0.00219	0.0024	CbGpPWpGaD
Ximelagatran—F2—GPCR downstream signaling—PENK—Parkinson's disease	0.00218	0.00239	CbGpPWpGaD
Ximelagatran—F2—Hemostasis—FGB—Parkinson's disease	0.00218	0.00238	CbGpPWpGaD
Ximelagatran—F2—Metabolism of proteins—RPL14—Parkinson's disease	0.00217	0.00238	CbGpPWpGaD
Ximelagatran—F2—Metabolism of proteins—RPL23A—Parkinson's disease	0.00217	0.00238	CbGpPWpGaD
Ximelagatran—CYP2C9—Biological oxidations—MAOB—Parkinson's disease	0.00217	0.00237	CbGpPWpGaD
Ximelagatran—F2—Class A/1 (Rhodopsin-like receptors)—EDN1—Parkinson's disease	0.00215	0.00236	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—GRM4—Parkinson's disease	0.00209	0.00229	CbGpPWpGaD
Ximelagatran—F2—GPCR ligand binding—HTR7—Parkinson's disease	0.00205	0.00224	CbGpPWpGaD
Ximelagatran—F2—GPCR ligand binding—DRD2—Parkinson's disease	0.00205	0.00224	CbGpPWpGaD
Ximelagatran—F2—Metabolism of proteins—RPS8—Parkinson's disease	0.00202	0.00222	CbGpPWpGaD
Ximelagatran—F2—GPCR downstream signaling—PDYN—Parkinson's disease	0.00199	0.00218	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—PENK—Parkinson's disease	0.00198	0.00217	CbGpPWpGaD
Ximelagatran—F2—Class A/1 (Rhodopsin-like receptors)—HTR2A—Parkinson's disease	0.00188	0.00206	CbGpPWpGaD
Ximelagatran—F2—GPCR downstream signaling—GRM5—Parkinson's disease	0.00185	0.00203	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—DGKQ—Parkinson's disease	0.00182	0.00199	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—GPR37—Parkinson's disease	0.00182	0.00199	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—PDYN—Parkinson's disease	0.00181	0.00198	CbGpPWpGaD
Ximelagatran—F2—Selenium Micronutrient Network—IL6—Parkinson's disease	0.0018	0.00197	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—GRM5—Parkinson's disease	0.00168	0.00184	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—PPP1R1B—Parkinson's disease	0.00166	0.00182	CbGpPWpGaD
Ximelagatran—F2—GPCR ligand binding—EDN1—Parkinson's disease	0.00164	0.00179	CbGpPWpGaD
Ximelagatran—F2—Hemostasis—SOD1—Parkinson's disease	0.00162	0.00177	CbGpPWpGaD
Ximelagatran—CYP2C9—Biological oxidations—CYP2D6—Parkinson's disease	0.00161	0.00176	CbGpPWpGaD
Ximelagatran—CYP2C9—Metapathway biotransformation—CYP2D6—Parkinson's disease	0.00159	0.00174	CbGpPWpGaD
Ximelagatran—F2—GPCR downstream signaling—ADORA2A—Parkinson's disease	0.00158	0.00173	CbGpPWpGaD
Ximelagatran—F2—Hemostasis—ABL1—Parkinson's disease	0.00154	0.00169	CbGpPWpGaD
Ximelagatran—F2—Hemostasis—IGF2—Parkinson's disease	0.00153	0.00168	CbGpPWpGaD
Ximelagatran—CYP2C9—Biological oxidations—CYP2E1—Parkinson's disease	0.00147	0.00161	CbGpPWpGaD
Ximelagatran—CYP2C9—Metapathway biotransformation—CYP2E1—Parkinson's disease	0.00145	0.00159	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—RIT2—Parkinson's disease	0.00145	0.00159	CbGpPWpGaD
Ximelagatran—F2—Hemostasis—HGF—Parkinson's disease	0.00145	0.00159	CbGpPWpGaD
Ximelagatran—F2—GPCR ligand binding—HTR2A—Parkinson's disease	0.00143	0.00157	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—ADORA2A—Parkinson's disease	0.00143	0.00157	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—GRK5—Parkinson's disease	0.00138	0.00151	CbGpPWpGaD
Ximelagatran—F2—GPCR downstream signaling—HTR1A—Parkinson's disease	0.00137	0.0015	CbGpPWpGaD
Ximelagatran—F2—GPCR downstream signaling—TAC1—Parkinson's disease	0.00135	0.00147	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism of lipids and lipoproteins—GBA—Parkinson's disease	0.00135	0.00147	CbGpPWpGaD
Ximelagatran—F2—GPCR downstream signaling—DRD1—Parkinson's disease	0.00132	0.00145	CbGpPWpGaD
Ximelagatran—F2—GPCR downstream signaling—DRD3—Parkinson's disease	0.00128	0.0014	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—HTR1A—Parkinson's disease	0.00124	0.00136	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—GRM4—Parkinson's disease	0.00123	0.00135	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—TAC1—Parkinson's disease	0.00122	0.00134	CbGpPWpGaD
Ximelagatran—CYP2C9—Biological oxidations—COMT—Parkinson's disease	0.00122	0.00134	CbGpPWpGaD
Ximelagatran—CYP2C9—Biological oxidations—GSTP1—Parkinson's disease	0.00121	0.00133	CbGpPWpGaD
Ximelagatran—CYP2C9—Biological oxidations—MAOA—Parkinson's disease	0.00121	0.00133	CbGpPWpGaD
Ximelagatran—F2—Metabolism of proteins—IGF2—Parkinson's disease	0.00121	0.00132	CbGpPWpGaD
Ximelagatran—CYP2C9—Metapathway biotransformation—COMT—Parkinson's disease	0.0012	0.00132	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—DRD1—Parkinson's disease	0.0012	0.00131	CbGpPWpGaD
Ximelagatran—CYP2C9—Metapathway biotransformation—GSTP1—Parkinson's disease	0.0012	0.00131	CbGpPWpGaD
Ximelagatran—F2—GPCR downstream signaling—ADRBK1—Parkinson's disease	0.00119	0.00131	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—PENK—Parkinson's disease	0.00117	0.00128	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—MAG—Parkinson's disease	0.00117	0.00128	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—DRD3—Parkinson's disease	0.00116	0.00127	CbGpPWpGaD
Ximelagatran—F2—GPCR downstream signaling—HTR7—Parkinson's disease	0.00116	0.00127	CbGpPWpGaD
Ximelagatran—F2—GPCR downstream signaling—DRD2—Parkinson's disease	0.00116	0.00127	CbGpPWpGaD
Ximelagatran—CYP2C9—Biological oxidations—GSTM1—Parkinson's disease	0.00112	0.00122	CbGpPWpGaD
Ximelagatran—CYP2C9—Metapathway biotransformation—GSTM1—Parkinson's disease	0.0011	0.0012	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—ADRBK1—Parkinson's disease	0.00108	0.00119	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—PDYN—Parkinson's disease	0.00107	0.00117	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—HTR7—Parkinson's disease	0.00105	0.00115	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—DRD2—Parkinson's disease	0.00105	0.00115	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—GFAP—Parkinson's disease	0.00101	0.0011	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—GRM5—Parkinson's disease	0.000995	0.00109	CbGpPWpGaD
Ximelagatran—F2—GPCR downstream signaling—EDN1—Parkinson's disease	0.000926	0.00101	CbGpPWpGaD
Ximelagatran—F2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Parkinson's disease	0.000883	0.000966	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—FGF20—Parkinson's disease	0.000872	0.000955	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—ADORA2A—Parkinson's disease	0.000846	0.000926	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—EDN1—Parkinson's disease	0.000841	0.000921	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G6—Parkinson's disease	0.00084	0.00092	CbGpPWpGaD
Ximelagatran—F2—GPCR downstream signaling—HTR2A—Parkinson's disease	0.00081	0.000887	CbGpPWpGaD
Ximelagatran—F2—Metabolism of proteins—INS—Parkinson's disease	0.000801	0.000877	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—ND3—Parkinson's disease	0.000791	0.000866	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—MCCC1—Parkinson's disease	0.000791	0.000866	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—INSR—Parkinson's disease	0.00078	0.000855	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—TALDO1—Parkinson's disease	0.000744	0.000814	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—OMD—Parkinson's disease	0.000744	0.000814	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—FGB—Parkinson's disease	0.000738	0.000808	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—HTR2A—Parkinson's disease	0.000736	0.000806	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—HTR1A—Parkinson's disease	0.000734	0.000803	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—TAC1—Parkinson's disease	0.000723	0.000791	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—DRD1—Parkinson's disease	0.000709	0.000776	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—NDUFB11—Parkinson's disease	0.000705	0.000772	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—DRD3—Parkinson's disease	0.000686	0.000752	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—GCH1—Parkinson's disease	0.000673	0.000736	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—ADRBK1—Parkinson's disease	0.000641	0.000702	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—DRD2—Parkinson's disease	0.000621	0.00068	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—HTR7—Parkinson's disease	0.000621	0.00068	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—Parkinson's disease	0.000607	0.000664	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—DBH—Parkinson's disease	0.0006	0.000656	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—FBP1—Parkinson's disease	0.0006	0.000656	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—GBA—Parkinson's disease	0.0006	0.000656	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—IGF2—Parkinson's disease	0.00052	0.00057	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—IGF1R—Parkinson's disease	0.000503	0.000551	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—EDN1—Parkinson's disease	0.000497	0.000544	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—NGF—Parkinson's disease	0.000457	0.0005	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—DDC—Parkinson's disease	0.00044	0.000482	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—HTR2A—Parkinson's disease	0.000435	0.000476	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—GSTA4—Parkinson's disease	0.000416	0.000455	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—Parkinson's disease	0.00041	0.000449	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—APOE—Parkinson's disease	0.000404	0.000443	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—PLA2G6—Parkinson's disease	0.000374	0.00041	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—MAOB—Parkinson's disease	0.00037	0.000406	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism of lipids and lipoproteins—APOE—Parkinson's disease	0.000353	0.000386	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—INS—Parkinson's disease	0.000345	0.000378	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—CYP2D6—Parkinson's disease	0.000275	0.000301	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—CTGF—Parkinson's disease	0.00027	0.000296	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—CASP3—Parkinson's disease	0.000257	0.000281	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—IL6—Parkinson's disease	0.000255	0.00028	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—CYP2E1—Parkinson's disease	0.000252	0.000276	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—NQO1—Parkinson's disease	0.000249	0.000273	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—TH—Parkinson's disease	0.000245	0.000269	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—MAPK8—Parkinson's disease	0.000236	0.000259	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—CYCS—Parkinson's disease	0.000236	0.000258	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—COMT—Parkinson's disease	0.000209	0.000228	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—GSTP1—Parkinson's disease	0.000208	0.000227	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—MAOA—Parkinson's disease	0.000207	0.000227	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—HMOX1—Parkinson's disease	0.000205	0.000224	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—ABCB1—Parkinson's disease	0.000197	0.000215	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—GSTM1—Parkinson's disease	0.000191	0.000209	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—GPX1—Parkinson's disease	0.000183	0.0002	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—MTHFR—Parkinson's disease	0.000169	0.000185	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—APOE—Parkinson's disease	0.000157	0.000172	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—IL6—Parkinson's disease	0.000151	0.000165	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—INS—Parkinson's disease	0.000134	0.000147	CbGpPWpGaD
